News |  Sitemap |  Contact
PDF Export  | 

Gilbert Bigras: HER-2/NEU AMPLIFIED BREAST CANCERS HAVE LARGE AMOUNT OF CYTOPLASM AS DETERMINED BY IMAGE-ANALYSIS WITH IMAGEJ SOFTWARE

Abstract

HER-2/neu is a cellular membrane protein which belongs to growth factor receptors family and is often targeted for breast cancer therapy. In HER2/neu assessment, image-analysis is generally used for HER2/neu immunohistochemical staining quantitation as viable alternative to manual scoring in order to enhance reproducibility and reliability. Repeated observations of amplified versus non-amplified HER-2/neu breast cancers rose the hypothesis of correlation between the amount of tumoural cytoplasm and HER2/neu amplification. Status of HER2/neu amplification of 477 consecutive breast cancers was first triaged with immunohistochemistry (A0485 polyclonal antibody, DakoCytomation, Carpinteria,CA, USA). Seventy-two breast cancers (15%) were found amplified which was confirmed with chromogenic in situ hybridization study. An imageJ macro was designed to compute the ratio cytoplasmic volume/tumoral volume (Cv/Tv) based on volume fraction stereological estimator. Cv/Tv was found significantly higher in the HER2/neu amplified group. This finding is easily explained by the biological role of growth factor receptor: when activated it will among others things promote intrinsic cellular growth via ribogenesis. Consequently the cytoplasm expands. The authors suggest to use this morphometric parameter as a supplementary checkpoint in HER2/neu assessment.

Keywords

breast cancer, Her2, stereology, volume fraction

Administrative data

Presenting author: Gilbert Bigras
Organisation: Cross Cancer Institute, Laboratory Medicine University of Alberta, 11560 University Avenue, Edmonton, Alberta CANADA

co-authors: Jean Deschênes

Kim Formenti

Melissa Gray

Christina Dao

Sarah Mitchell

Type: Poster (landscape)

© Luxembourg Institute of Science and Technology | Legal Notice